Similar articles

• [Conventional basis therapy of rheumatoid arthritis. Effects within and outside cells].

  Keyßer G. Keyßer G. Z Rheumatol. 2012 Aug;71(6):468-72. doi: 10.1007/s00393-011-0878-3. Z Rheumatol. 2012. PMID: 22802023 German.
• [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].

  Frommer KW, Geyer M, Firestein GS. Frommer KW, et al. Z Rheumatol. 2012 Aug;71(6):460-7. doi: 10.1007/s00393-011-0877-4. Z Rheumatol. 2012. PMID: 22875571 German.
• Review: basics of drug development in rheumatology.

  Mina-Osorio P. Mina-Osorio P. Arthritis Rheumatol. 2015 Oct;67(10):2581-90. doi: 10.1002/art.39253. Arthritis Rheumatol. 2015. PMID: 26138901 Review. No abstract available.
• [New kinase inhibitors].

  Rubbert-Roth A. Rubbert-Roth A. Z Rheumatol. 2012 Aug;71(6):479-84. doi: 10.1007/s00393-011-0880-9. Z Rheumatol. 2012. PMID: 22777068 German.
• The IL-17 pathway as a major therapeutic target in autoimmune diseases.

  Hu Y, Shen F, Crellin NK, Ouyang W. Hu Y, et al. Ann N Y Acad Sci. 2011 Jan;1217:60-76. doi: 10.1111/j.1749-6632.2010.05825.x. Epub 2010 Dec 13. Ann N Y Acad Sci. 2011. PMID: 21155836 Review.